Cases
Myriad Genetics, Inc. (MYGN)
Securities Class Action
Overview
Overview
- Date:
- 3/19/2018
- Company Name:
- Myriad Genetics, Inc.
- Stock Symbol:
- MYGN
- Status:
- Closed/Complete
NEW YORK, April 23, 2018 – Bragar Eagel & Squire, P.C. announces to investors that a class action lawsuit has been filed in the U.S. District Court for the District of Utah on behalf of all persons or entities who purchased or otherwise acquired Myriad Genetics, Inc. (NASDAQ: MYGN) securities between August 13, 2014 and March 12, 2018 (the “Class Period”). Investors have until June 19, 2018 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
On March 12, 2018, Myriad announced that the Company had recently received a Subpoena from the Department of Health and Human Services, Office of Inspector General, in connection with an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid. The Subpoena requested that the Company produce documents relating primarily to the Company’s billing to government-funded healthcare programs for the Company’s hereditary cancer testing.
Following this news, shares of Myriad fell $4.01 per share, or 12.1%, to close at $29.01 on March 13, 2018.
If you purchased or otherwise acquired Myriad securities during the Class Period or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
On March 12, 2018, Myriad announced that the Company had recently received a Subpoena from the Department of Health and Human Services, Office of Inspector General, in connection with an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid. The Subpoena requested that the Company produce documents relating primarily to the Company’s billing to government-funded healthcare programs for the Company’s hereditary cancer testing.
Following this news, shares of Myriad fell $4.01 per share, or 12.1%, to close at $29.01 on March 13, 2018.
If you purchased or otherwise acquired Myriad securities during the Class Period or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.